Literature DB >> 17228556

Understanding hypoxia signalling in cells--a new therapeutic opportunity?

Peter J Ratcliffe1.   

Abstract

The possibility that cells possess specific interfaces with molecular oxygen that have a prime function in biological control has long interested biologists. Specific 'oxygen-sensing' mechanisms have been defined in bacteria and yeast, but, until recently, have remained elusive in higher organisms. Studies of hypoxia pathways have now, however, revealed the existence of a series of non-haem Fe(ll) and 2-oxoglutarate-dependent dioxygenases that catalyse oxygen-regulated hydroxylation of specific amino acids in a key transcription factor termed hypoxia-inducible factors (HIFs). These post-translational hydroxylations govern both the proteolytic stability and activity of HIF and therefore the transcription of many hundreds of human genes whose expression changes in accordance with cellular oxygen availability. This paper will review these developments and consider the biological and potential therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17228556      PMCID: PMC4952769          DOI: 10.7861/clinmedicine.6-6-573

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  10 in total

1.  α-Ketoglutarate-related inhibitors of HIF prolyl hydroxylases are substrates of renal organic anion transporters 1 (OAT1) and 4 (OAT4).

Authors:  Yohannes Hagos; Gunnar Schley; Johannes Schödel; Wolfgang Krick; Gerhard Burckhardt; Carsten Willam; Birgitta C Burckhardt
Journal:  Pflugers Arch       Date:  2012-08-09       Impact factor: 3.657

2.  William Kaelin, Peter Ratcliffe, and Gregg Semenza receive the 2016 Albert Lasker Basic Medical Research Award.

Authors:  Jillian H Hurst
Journal:  J Clin Invest       Date:  2016-09-13       Impact factor: 14.808

3.  Stimulating retinal blood vessel protection with hypoxia-inducible factor stabilization: identification of novel small-molecule hydrazones to inhibit hypoxia-inducible factor prolyl hydroxylase (an American Ophthalmological Society thesis).

Authors:  Jonathan E Sears; George Hoppe
Journal:  Trans Am Ophthalmol Soc       Date:  2013-09

4.  A novel erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove.

Authors:  Melanie J Percy; Paul W Furlow; Philip A Beer; Terence R J Lappin; Mary Frances McMullin; Frank S Lee
Journal:  Blood       Date:  2007-06-19       Impact factor: 22.113

5.  Prolyl hydroxylase inhibition during hyperoxia prevents oxygen-induced retinopathy.

Authors:  Jonathan E Sears; George Hoppe; Quteba Ebrahem; Bela Anand-Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-04       Impact factor: 11.205

Review 6.  Recently published papers: the Jekyll and Hyde of oxygen, neuromuscular blockade and good vibrations?

Authors:  Jonathan Ball
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

7.  Association of erythropoietin gene rs576236 polymorphism and risk of adrenal tumors in a Chinese population.

Authors:  Chao Zhang; Zhongxing Li; Qiang Cao; Chao Qin; Hongzhou Cai; Hai Zhou; Jian Qian; Liangjun Tao; Xiaobing Ju; Changjun Yin
Journal:  J Biomed Res       Date:  2014-08-11

8.  CA9 Silencing Promotes Mitochondrial Biogenesis, Increases Putrescine Toxicity and Decreases Cell Motility to Suppress ccRCC Progression.

Authors:  Jiatong Xu; Songbiao Zhu; Lina Xu; Xiaohui Liu; Wenxi Ding; Qingtao Wang; Yuling Chen; Haiteng Deng
Journal:  Int J Mol Sci       Date:  2020-08-18       Impact factor: 5.923

9.  The increase in pulmonary arterial pressure caused by hypoxia depends on iron status.

Authors:  Thomas G Smith; George M Balanos; Quentin P P Croft; Nick P Talbot; Keith L Dorrington; Peter J Ratcliffe; Peter A Robbins
Journal:  J Physiol       Date:  2008-10-27       Impact factor: 5.182

10.  Distinct mechanisms underlying tolerance to intermittent and constant hypoxia in Drosophila melanogaster.

Authors:  Priti Azad; Dan Zhou; Erilynn Russo; Gabriel G Haddad
Journal:  PLoS One       Date:  2009-04-29       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.